+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Market Spotlight: Acute Lymphoblastic Leukemia (ALL)

  • Report

  • 44 Pages
  • February 2021
  • Region: Global
  • Citeline
  • ID: 4846155
This Market Spotlight report covers the Acute Lymphoblastic Leukemia (ALL) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming events, probability of success, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways
  • The publisher estimates that in 2018, there were 86,600 incident cases of acute lymphoblastic leukemia (ALL) worldwide, and expects that number to increase to 93,500 incident cases by 2027.
  • Approved drugs in the ALL space focus on a wide variety of targets. The majority of these therapies are administered via the intravenous route, with the remaining products being available in oral and intramuscular formulations.
  • The highest proportion of industry-sponsored drugs in active clinical development for ALL are in Phase I, with only one drug in the NDA/BLA phase.
  • Therapies in development for ALL focus on a wide variety of targets. The majority of pipeline drugs in development are administered via the intravenous route, with the remainder being oral and intramuscular formulations.
  • High-impact upcoming events for drugs in the ALL space comprise topline Phase II trial results for Sarclisa, and an expected supplemental BLA filing for Tecartus.
  • The overall likelihood of approval of a Phase I hematologic asset is 8.7%, and the average probability a drug advances from Phase III is 58.9%. Drugs, on average, take 9.4 years from Phase I to approval, compared to 9.6 years in the overall oncology space.
  • The distribution of clinical trials across Phase I–IV indicates that the vast majority of trials for ALL have been in the early and midphases of development, with 92% of trials in Phase I–II, and only 8% in Phase III–IV.
  • The US has a substantial lead in the number of ALL clinical trials globally. France leads the major European markets, while China has the top spot in Asia.
  • Novartis has the highest number of completed clinical trials for ALL, with 47 trials.
  • Novartis also leads industry sponsors with the highest overall number of clinical trials for ALL

Table of Contents

OVERVIEWKEY TAKEAWAYS
DISEASE BACKGROUND
  • Definition
  • Patient segmentation
  • Symptoms
  • Risk factors
  • Diagnosis

TREATMENT
  • Chemotherapy
  • Corticosteroids
  • TKI therapy
  • Immunotherapy
  • Radiation therapy
  • Stem cell transplant

EPIDEMIOLOGYMARKETED DRUGSPIPELINE DRUGS
RECENT EVENTS AND ANALYST OPINION
  • Blincyto for ALL (December 10, 2019)
  • GC022 for ALL (December 7, 2019)
  • Blincyto for ALL (September 24, 2019)

KEY UPCOMING EVENTSPROBABILITY OF SUCCESS
LICENSING AND ASSET ACQUISITION DEALS
  • ADC Therapeutics In Asia JV, License Deal With Overland

REVENUE OPPORTUNITY
CLINICAL TRIAL LANDSCAPE
  • Sponsors by status
  • Sponsors by phase

BIBLIOGRAPHY
  • Prescription information

APPENDIX
LIST OF FIGURES
Figure 1: Trends in incident cases of ALL, 2018–27
Figure 2: Overview of pipeline drugs for ALL in the US
Figure 3: Pipeline drugs for ALL, by company
Figure 4: Pipeline drugs for ALL, by drug type
Figure 5: Pipeline drugs for ALL, by classification
Figure 6: Blincyto for ALL (September 24, 2019): Phase III - Pediatric (1st Relapse)
Figure 7: Key upcoming events in ALL
Figure 8: Probability of success in the hematologic pipeline
Figure 9: Clinical trials in ALL
Figure 10: Top 10 drugs for clinical trials in ALL
Figure 11: Top 10 companies for clinical trials in ALL
Figure 12: Trial locations in ALL
Figure 13: ALL trials status
Figure 14: ALL trials sponsors, by phase
LIST OF TABLES
Table 1: Incident cases of ALL, 2018–27
Table 2: Marketed drugs for ALL
Table 3: Pipeline drugs for ALL in the US
Table 4: Blincyto for ALL (December 10, 2019)
Table 5: GC022 for ALL (December 7, 2019)
Table 6: Blincyto for ALL (September 24, 2019)
Table 7: Historical global sales, by drug ($m), 2015–19
Table 8: Forecasted global sales, by drug ($m), 2021–25